Ascentage Pharma to Showcase Six ASCO 2026 Abstracts Including Three Rapid Orals
Ascentage Pharma will present six clinical abstracts, including three rapid oral presentations, at the ASCO Annual Meeting May 29–June 2 in Chicago and online. Data cover Olverembatinib, Lisaftoclax and Alrizomadlin trials ranging from CML and Ph+ ALL to pediatric sarcomas, underpinning global development progress.
1. ASCO Presentation Overview
Ascentage Pharma has secured six abstract selections for the ASCO Annual Meeting, including three rapid oral and three poster presentations. This marks the company’s ninth consecutive year at the meeting, highlighting its commitment to advancing novel oncology therapies on a global stage.
2. Rapid Oral Presentation Details
Three rapid oral sessions will feature Olverembatinib combined with blinatumomab in CML-LBP and Ph+ BCP-ALL, updated second-line efficacy and safety of Olverembatinib in CP-CML, and Alrizomadlin alone or with Lisaftoclax for relapsed pediatric sarcomas. Sessions are scheduled May 30–31, spotlighting hematologic malignancies and pediatric oncology.
3. Poster Presentations and Ongoing Trials
Three poster presentations include updated results of Olverembatinib in SDH-deficient tumors, a phase 3 POLARIS-2 trial in CP-CML, and the phase 3 GLORA trial of Lisaftoclax in CLL/SLL. These studies underscore Ascentage Pharma’s expanding late-stage pipeline and global registrational efforts.